Clinical trial Recruiting at 1 site Interventional Ages 65 and up

Esketamine combined with dexmedetomidine to improve sleep after hip fracture surgery

Official title: Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality in Elderly Patients Undergoing Hip Surgery:A Superiority Randomized Controlled Trail

Run by Peking University Shenzhen Hospital · NCT07002723 · Data updated 2026-11-12

This will test whether giving esketamine together with dexmedetomidine during and after neuraxial anesthesia helps people 65 and older who have hip fracture surgery sleep better and have less pain and confusion.

More Hip Fractures trials

Quick facts

Study typeInterventional
Ages65 Years and up
SexAll
Enrollment96 (estimated)
SponsorPeking University Shenzhen Hospital
Academic / other
Locations1 site (Shenzhen, Guangdong)
StatusRecruiting
StartedJune 20, 2025
Main results expectedJune 30, 2026
Study endsJune 30, 2026
Registry record updatedDecember 5, 2025
Trial IDNCT07002723 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged 65 or older undergoing hip fracture surgery under neuraxial anesthesia who can provide informed consent and have no contraindications to esketamine or dexmedetomidine.

Probably not a fit

Patients with severe cardiovascular disease, obstructive sleep apnea, significant hepatic or renal failure, contraindications to neuraxial anesthesia, or known allergies to the study drugs are unlikely to benefit and are excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Older patients having hip fracture surgery are randomly assigned to receive either an infusion of esketamine plus dexmedetomidine or a matching saline infusion starting after neuraxial anesthesia and continuing for 48 hours. Baseline and postoperative measures include sleep quality (PSQI), delirium screening (3D-CAM), cognitive testing (MoCA), mood (HADS), and pain scores (FPS-R and NRS), along with routine labs. Morphine is given epidurally at surgery start in both groups, and long-term cognitive and recovery outcomes are followed by telephone. The protocol is conducted at a single center with in-hospital monitoring during the infusion period.

Why it matters

Potential benefit: If successful, the drug combination could improve postoperative sleep, reduce pain and delirium, and support better cognitive recovery after hip fracture surgery.

How similar studies have gone: Dexmedetomidine alone has shown some benefit for sleep and delirium prevention in older surgical patients, but combining esketamine with dexmedetomidine is relatively novel with limited prior data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age≥ 65 years old;
* Hip fracture surgery under neuraxial anesthesia;
* Signed informed consent.

Exclusion Criteria:

* ASA classification≥ Class V;
* Presence of neuraxial anesthesia contraindications: coagulation dysfunction, thrombocytopenia, neuraxial mass, puncture site infection, etc.;
* Patients with contraindications to esketamine (such as allergies, intracranial aneurysms, hyperthyroidism and glaucoma);
* Patients with contraindications to dexmedetomidine (allergies);
* Patients with severe cardiovascular diseases such as sick sinus syndrome, severe sinus bradycardia (heart rate \< 50 beats/min), atrioventricular block grade II or above without pacemaker, unstable angina, severe valvular heart disease, severe arrhythmia, severe macrovascular disease with New York Heart Association class III patients, etc.;
* Obstructive sleep apnea syndrome (STOP-BANG score \> 3 points);
* Patients with severe hepatic and renal insufficiency (such as Child-Pugh score III, creatinine clearance \< 35 mL/min, preoperative dialysis);
* Those who have delirium, dementia, moderate to severe cognitive dysfunction and psychiatric disorders before the start of the trial and are unable to communicate and cooperate with the investigator.

Where it's running

  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong, China
    Recruiting

Study contacts

  • Principal investigator: Tao Luo, MD,PhD — Peking University Shenzhen Hospitai
  • Study coordinator: Tao Luo, MD,PhD
  • Email: luotao_wh@yahoo.com
  • Phone: 13510820779

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.